opnMe online seminar

What is the seminar about?

Pancreatic cancer is one of the most challenging cancer diseases to treat due to its intricate biology. But what if we could harness the power of donated chemical probes, collaborative networks, and shared knowledge to unravel these complexities? Join our live online seminar and learn more about our glucocorticoid receptor agonist, BI-653048, and its journey through open innovation initiatives such as the Structural Genomics Consortium (SGC)¹, the Donated Chemical Probes (DCP)² program, and opnMe to the scientific community. Hear from Susanne Müller-Knapp and Florian Montel as they discuss how initiatives like SGC, DCP, and opnMe are expanding the boundaries of academic innovation in cancer research. Thomas Ekstrom will focus on the science of glucocorticoid receptor signaling and how these open innovation platforms helped him in his latest discoveries in small molecule screening and how they overall are helping to advance our understanding of pancreatic cancer subtypes³.

Why should you attend?

In this interactive seminar, you will:

• Discover how SGC, DCP, and opnMe have inspired and paved the way for new independent findings in cancer research
• Learn how BI-653048 helped to unravel subtype identities in pancreatic cancer
• Engage directly with the experts and get inspired for your own research
• Get an official opnMe certificate of attendance*

SECURE YOUR SPOT

About the speakers

Susanne Müller-Knapp

Susanne holds a PhD in Biology and is Chief Operating Officer of the SGC-Frankfurt and Director of Operations of the Chemical Probes Portal, a free, public online resource of expert reviews and evaluations of chemical probes. In addition, she is Head of Project Management Office for EUbOPEN and works as a group leader at the Goethe University, Frankfurt. Her research focuses on using chemical biology to evaluate the role of a specific target in biology and disease by developing assays to study cellular on-target effects, permeability, general toxicity, unspecific compound effects, and phenotypic effects of small molecule modulators.

Thomas Ekstrom

Thomas holds a Bachelor of Science from the University of Minnesota Rochester and is currently working as a PhD candidate at the Robert Bosch Center for Tumor Diseases in Stuttgart. His research centers around identifying the mechanisms of subtype-identity defining transcription factors in pancreatic cancer, their role in controlling phenotypic plasticity, and the utility of targeting these programs to increase therapeutic efficacy in pancreatic cancer.

Florian Montel

Florian, who holds a PhD in Chemistry, leads the opnMe.com team and heads the OpenScience group at Boehringer Ingelheim. His focus is on overseeing the company’s open innovation initiatives, from opnMe to the coordination of the Public-Private-Partnerships funded by IHI and the collaborations with the BioMed X institute. His motivation is to openly share Boehringer’s scientific challenges and assets to foster academic innovation and accelerate the development of new treatments for patients in need.

REGISTER TODAY

References

¹ Home | Structural Genomics Consortium

² Donated chemical probes | Structural Genomics Consortium

³ Ekstrom T. L., Rosok R. M., Abdelrahman A. M., Parassiadis C., Manjunath M., Dittrich M. Y., Wang X., Kutschat A. P., Kanakan A., Rajput A., Schacherer N., Lukic T., Carlson D. M., Thiel J., Kopp W., Stroebel P., Ellenrieder V., Gaedcke J., Dong M., Najafova Z., Truty M. J., Hessmann E., Johnsen S. A. Glucocorticoid receptor suppresses GATA6-mediated RNA polymerase II pause release to modulate classical subtype identity in pancreatic cancer Gut. 2025, Jan 30. DOI: 10.1136/gutjnl-2024-334374.

*Please note that the name and email address you provide during registration will be used to generate your certificate of attendance.